Live Chat ×
Skip to main content

Medical Communications for Emerging versus Established Markets

Description

This will be our 4th MedComms Networking Virtual Event and we're delighted to be working with HealthCare21 Communications, on this programme to address the following questions:

  • What are the healthcare dynamics and challenges of the key emerging markets?
  • What are the educational needs of the emerging markets and how can tailored medical communications best address them?
  • What does the future hold for medical communications in the emerging markets?
Once again, we’ve lined up a panel of experts and the emphasis in the meeting will be on encouraging the audience to ask questions and share their own experiences. Join us, from wherever in the world you are. Everyone welcome. Please help spread the word. Get some cake in and gather your team together and join in as a group.

These virtual meetings are supported by Blue Sky eLearn.

Contributors

  • Peter Llewellyn, Managing Director, NetworkPharma Ltd. and Founder of the MedComms Networking Community

    With a background in pharma, e-comms, marketing, medical communications and publishing work, Peter is now involved in a diverse range of activities. MedComms Networking, which celebrated its 10 year anniversary in 2017, is a global initiative that facilitates networking and dialogue amongst individuals working in and around the pharmaceutical industry and MedComms, focusing on specialist medical education, medical communications and medical publishing activities.

  • Dr. Genevieve Chase, Client Services Lead, HealthCare21 Singapore

    Genevieve has over 20 years’ experience spanning research, publications, medical writing, project management and supervision, protocol development, education and client liaison in academia and the pharmaceutical industry. She gained her PhD in Australia then carried out postdoctoral research in the US, before moving to Singapore to work in MedComms. This background has provided her with extensive experience in many therapeutic areas, including aesthetics, cardiovascular disease, diabetes, multiple sclerosis, oncology, pain and vaccines, and an abundance of healthcare knowledge in developing and emerging markets.

  • Dr. Sally Stringer, Scientific Director, HealthCare21 Communications

    Sally is responsible for ensuring that the medical communication and education delivered by her team of writers and editors has the right strategic medical and scientific messages and is of the highest quality. This includes a variety of engaging approaches, such as virtual advisory boards and learning platforms, web workshops, animations and infographics, aimed at improving management and treatment of patients with long-term conditions. Her role has included working with emerging markets where she has gained insights into the challenges met by local physicians. Prior to her seven years in the industry, Sally was a research team leader and lecturer, has over 30 publications drawn from her own research, and has worked as an Assistant Professor in the US and Australia.

  • Stephen Doyle, GM Head of China and Global Head of Commercial Operations, ASLAN Pharmaceuticals

    Stephen has 20 years’ experience in sales and marketing across different specialties within the medical sector in both developed and emerging markets. Career highlights include driving study concepts through inception, clinical development, publication, regulatory and health board approval in-market; lifecycle management success in bringing unique indication extension to products in China; and extensive experience in all aspects of change management demonstrated by the successful integration, management and reorganisation of Genzyme with Sanofi in China, and Aventis with Sanofi in Australia. Stephen has been a teacher of pharmaceutical marketing within the Medical Affairs China development programme, a commercial expert and lecturer at biosimilar conferences in China, and is also a passionate oncology advocate currently serving on the board of the CEO Roundtable on Cancer in China.

  • Pascal Rufi, Medical Multiple Sclerosis Lead, General Medicines and Emerging Markets, Sanofi

    Pascal is the medical multiple sclerosis lead for GEM, Sanofi in Paris. He received his degree in medicine and biostatistics from the Strasbourg Medical University. Pascal has been working at Sanofi for 22 years and has held different positions within R&D and Global franchises across different therapy areas, including multiple sclerosis, internal medicine, cardiology and diabetes.

October 4, 2018
Thu 1:00 PM BST

Duration 1H 0M

Already Registered? System Requirements »